Jun 22, 2020 5:15pm EDT Medexus Pharmaceuticals Reports Record Revenue of $25.6 Million and $4.2 Million of Adjusted EBITDA* for the Fourth Quarter of Fiscal 2020
May 22, 2020 8:51am EDT Medexus Provides an Update on the IXINITY® Acquisition and its Overall Business in the COVID-19 Environment
May 07, 2020 5:00pm EDT Medexus Announces US$20 Million Asset-Based Credit Facility and Repays US$10 Million of its Term Loan
Apr 08, 2020 8:30am EDT Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Public Reimbursement in Canada
Mar 23, 2020 8:30am EDT Medexus Provides a Business Update and Outlines Response to COVID-19 Pandemic
Feb 28, 2020 8:59am EST Medexus Expands its US Product Portfolio by Acquiring the Hematology Asset IXINITY®
Feb 18, 2020 6:52pm EST Medexus Pharmaceuticals Reports Revenue of $16.2 Million for the Third Quarter of Fiscal 2020
